AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04889794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GPS clinical intervention
Description: Nurses and doctors in exposed FMGs and home care teams (HCTs) will be asked to refer to the FMG pharmacist all seniors undergoing cognitive evaluation OR referred to a memory clinic OR recently diagnosed with a cognitive disorder, for a complete and critical review of their medication therapy. FMG pharmacists will be asked to conduct an interview with each referred senior and his or her caregiver, if applicable, in order to establish the best possible treatment regimen. They will compare the information collected with another reliable data source (e.g., pharmacy records) in order to perform medication reconciliation and will then evaluate the medication related problems. Pharmacist will establish a care plan and the follow-ups to be carried out with the patient in collaboration with the health care team. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
Study NCT04533165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 12 week exercise prescription targeting 3 days of at least 30 min of aerobic exercise and 2 days of resistance exercise per week. Adapted to individual abilities, goals, and needs. Exercise intensity targets a 6-7 out of 10 on a 0-10 rate of perceived exertion scale.
Study NCT06594094 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HG302
Description: Once intravenous injection; The duration of the study is about 32 weeks for each subject, including a 6 weeks screening period, enrollment visit, treatment visit, and 26 weeks follow-up period.
Study NCT06594445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTB-360
Description: GTB-3650 is administered by a continuous infusion (CI). A patient's dose of GTB-3650 is calculated using their assigned Dose Level and their actual body weight (ABW) obtained within 5 days prior to or on Cycle 1, Day 1.~Dose Level 1: 1.25 ug/kg/day Dose Level 2: 2.5 ug/kg/day Dose Level 3: 5 ug/kg/day Dose Level 4: 10 ug/kg/day Dose Level 5: 25 ug/kg/day Dose Level 6: 50 ug/kg/day Dose Level 7: 100 ug/kg/day
Study NCT06610279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-951
Description: TAK-951 SC injection
Study NCT06610279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-951 matching placebo SC injection
Study NCT06560541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UKMRC9
Description: UKMRC9 is a low glycemic index and polyphenol-rich red pigmented rice
Study NCT06560541 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White rice
Description: White rice refers to a local polished rice
Study NCT05003921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT04663815 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Animal-assisted activity
Description: The intervention is an animal-assisted activity consisting of a visit to Villa Samson (a place on the campus of the hospital specifically intended for patients to meet pets), where the child will work with a therapy dog for 1 hour. Under supervision, the animal is stroked and combed by the child, they play games together, the child feeds the animal, etc.
Study NCT04663815 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control intervention
Description: The control intervention reenacts a normal stay in the hospital, so the child spends one hour in the hospital room where the child can play, watch tv, etc.
Study NCT05360238 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-106
Description: T-cells derived from autologous leukapheresis that are genetically modified.
Study NCT05829408 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: KOPPeling
Description: KOPPeling lasts ten to twelve weeks and will be administered by health care professionals.
Study NCT05946993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dietitian Support
Description: The main goal of the nutritional intervention is to improve the diet quality of each patient using a standardized nutrition assessment, offering evidence-based diet group education and developing personalized nutrition goals. Participants will be progressively guided through the nutrition education programme; with modifications to the individual's usual diet, thereby recognizing personal eating patterns and preferences, which form the basis for individualized dietary counselling. The dietary counselling identifies the type, amount, and frequency of feeding and specifies the caloric/protein level to attain, together with any restrictions and limited or increased individual dietary components.
Study NCT05946993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing and Psychosocial
Description: Nursing, Psycho-oncology, pastoral care and social work-led sessions to inform participants on items including diagnosis shock, acceptance, coping with relationship changes with their partner and their roles, fear of uncertainty and the future, medication management, masculinity (male values being strong, capable, independent), practical management of bills, and household tasks. There will be an inclusion of practical information sessions including health systems information and managing side effects such as urinary symptoms, hot flushes, penile shortening, and loss of body hair.
Study NCT05928325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Complete geriatric assessments
Study NCT05928325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Receive survivorship care education
Study NCT05928325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear activity tracking device
Study NCT05873075 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravascular laser irradiation of blood
Description: Intravascular laser irradiation of blood via an intravenous catheter for irradiation of the blood under a period of 60 minutes daily for 20 days
Study NCT06010953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SS109
Description: on-demand treatment with SS109 at the time of a new hemorrhage event
Study NCT05928325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Receive geriatric assessment-guided interventions
Study NCT05359640 — intervention group
Intervention type: OTHER
Intervention: quality of pain
Description: We will recorded the pain by using a short pain questionnaire and a McGill pain questionnaire.
Study NCT06325098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Anti-nephrin antibodies
Description: Assessment of anti-nephrin antibodies on serum samples and in vitro study of permeabilizing effect on 3D organ-on-a-chip models and STED microscopy on healthy human kidneys.
Study NCT06325098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: u-RPC cultures
Description: Urine sample collection for u-RPC cultures
Study NCT05779046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT 1:1
Description: The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:1 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternating with low intensity 50-55% of maximum heart rate for 1 minute).
Study NCT05779046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT 1:2
Description: The participants received a high-intensity interval exercise program of walking or running on a treadmill for approximately 40 minutes. The training included a 10-minute warm-up at low intensity. High-intensity interval exercise at a ratio of 1:2 (high intensity for 1 minute at 85-90% of maximum heart rate, then alternate with low intensity 50-55% of maximum heart rate for 2 minutes).
Study NCT06535815 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cyclic enteral feeding with nighttime fasting and exogenous ketone salt supplementation (ß-hydroxybutyrate)
Description: 12 hours of enteral feeding (as per patients´individual calorimetric requirements measured by indirect calorimetry) followed by a fasting period of 12 hours supported by the supplementation of exogenous ketone salts.
Study NCT05218252 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Posterior interosseous artery flap
Description: The use of distally based posterior interosseous artery flap from the forearm in reconstructing mild to moderate hand soft tissue defects
Study NCT06268912 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Mepivacaine
Description: change the temperature, 3% at 5ºC
Study NCT06268912 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine at room temperature
Description: no change the temperature of anesthesia
Study NCT05072145 — intervention group
Intervention type: OTHER
Intervention: Telemedicine
Description: Receiving care in a tele-ED hospital
Study NCT05308576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTV01E
Description: D0; intramuscular injection
Study NCT05308576 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D0; intramuscular injection
Study NCT05130086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: 60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
Study NCT05675072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB2001
Description: FB2001 for Inhalation will be reconstituted with normal saline prior to nebulized inhalation. FB2001 will be administered by nebulized inhalation.
Study NCT05675072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FB2001 placebo
Description: FB2001 placebo will be reconstituted with normal saline prior to nebulized inhalation. FB2001 placebo will be administered by nebulized inhalation.
Study NCT05831267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fibrin Glue
Description: Blood samples were collected from the antecubital vein of the right or left arm of the patient and drawn into sterile Titanium tubes immediately. The tubes were then centrifuged for 12 minutes at 2800 rpm and room temperature
Study NCT05831267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T-PRF
Description: The contents of the two containers (human fibrinogen, human thrombin) will be mixed with distilled water and then aspirated by two syringes after that, the two solutions will be mixed together and injected into the empty compartment around the dental implant under the sinus mucosal lining using auto mixing applicator.
Study NCT05831267 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative control
Description: this group will not receive any material.
Study NCT06536075 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Sialoscintigraphy
Description: Sialoscintigraphy
Study NCT05194826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test
Description: immediate implant and VST with fascia lata membrane + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
Study NCT05194826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: immediate implant and VST with connective tissue graft + xenogenic lamina membrane and particulate bone graft composed of autogenous cortical chips harvested from the surgical site
Study NCT04719572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment group
Description: A total of 60 subjects were recruited in the group.
Study NCT04719572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment group
Description: A total of 60 subjects were recruited in the group.
Study NCT04719572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment+ anti-osteoporosis drug group
Description: A total of 60 subjects were recruited in the group.
Study NCT04719572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Basic treatment + non-drug treatment group
Description: A total of 60 subjects were recruited in the group.
Study NCT04719572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment + non-drug treatment group
Description: A total of 60 subjects were recruited in the group.
Study NCT06351891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline
Description: 14-day bismuth quadruple regimen containing cefuroxime and tetracycline:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Tetracycline 500mg tid,14 days.Evaluating the efficacy and safety of 14-Day bismuth quadruple therapy containing cefuroxime and tetracycline for Helicobacter pylori eradication.
Study NCT06351891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin
Description: 14-day bismuth quadruple regimen containing cefuroxime and levofloxacin:Tegoprazan 50mg bid, Bismuth potassium citrate capsules 0.6g bid,Cefuroxime tablets 500mg bid,Levofloxacin 500mg qd,14 days.
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib RP2D D1-14
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab 375 mg/m2 D0
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine per regimen dosage
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 D1
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 5g/m2 D2
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=5mg/mL · min (maximum absolute dose/cycle = 800 mg)
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100mg/m2 D1-3
Study NCT06392321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: comparison between bupivacaine, bupivacaine and fentanyl.
Study NCT06392321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: comparison between bupivacaine, bupivacaine and dexmedetomidine..
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40mg D1-4
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100mg/m2 D1, continuous intravenous infusion
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: Ara-C 2g/m2 q12h D2
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine 20mg/m2 D1
Study NCT06489808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: Mitoxantrone hydrochloride liposome 18mg/m2 D1
Study NCT05857046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 10 MG
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
Study NCT05857046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 10 MG
Description: Patients received extended-release melatonin 10 mg PO every 12 hours for 7 days and then every 24 hours for 83 days
Study NCT05857046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
Study NCT05857046 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received placebo every 12 hours for 7 days and then every 24 hours for 83 days
Study NCT06193993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Upon successful registration, patients would be initiated on 500 mg once daily (two 250 mg tablets), plus prednisolone 5 mg twice daily orally for mCRPC and 5mg once daily orally for mHSPC.
Study NCT04982042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
Study NCT04982042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: The Pulmonary Rehabilitation Program consists of a combination of aerobic and strengthening exercises, lasting 12 weeks, with a frequency of 3 times a week, always in the morning. Each session consists of active warm-up exercises, upper and lower limb strengthening, aerobic conditioning and stretching exercises. The warm-up phase consists of intercalated calisthenic exercises for different muscle groups, according to each patient's tolerance.
Study NCT04858737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-predictD-Work intervention
Description: The intervention is based on validated risk algorithms to predict depression and includes: 1) Mobile applications as main user's interface; 2) a DSS that helps worker participants to develop their own personalized plans to prevent (PPP) depression; 3) nine intervention modules (the core of the system) including activities to prevent depression, to be proposed by the DSS and chosen by the participants. The intervention is biopsychosocial and multi-component, including the following modules: physical exercise, improve sleep, expand relationships, solve problems, improve communication, assertiveness, decision making, manage thoughts and reduce work stress. Worker participants will implement the recommendations and the tool will monitor these actions, offering feedback to improve their PPP at 6 and 12 months.
Study NCT04858737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychoeducational messages
Description: The intervention consists of an App that weekly send short messages about stress and general health that will be extracted from brochures and websites of official agencies.
Study NCT05178628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Innohep
Description: Patients will receive Tinzaparin sodium 20.000 Anti-Xa IU/ml in prefilled syringes. Administered at 175 Anti-Xa IU/Kgr of body weight, subcutaneously, once daily
Study NCT05178628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy: Gemcitabine + Nab-Paclitaxel
Description: All patients will receive chemotherapy per clinical practice
Study NCT05422911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abiraterone acetate
Description: YONSA® (abiraterone acetate), YONSA® 500 mg (four 125 mg tablets) or 625 mg (five 125 mg tablets) administered orally once daily in combination with methylprednisolone 4 mg administered orally twice daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study NCT05422911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Apalutamide, 240 mg (four 60 mg tablets) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study NCT05422911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide, 160 mg (four 40 mg capsules) administered orally once daily + physician's choice GnRH agonist/antagonist \[unless the Veteran has had prior bilateral orchiectomy\].
Study NCT05085457 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ExPreS Protocol
Description: Prof, aqui explicamos o que é o ExPreS????? Já que ele fala para não repetir informação
Study NCT05707234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRH
Description: The VR headset and headphones will be placed on patients after the spinal anesthesia, once the patient is positioned and the surgical drapes installed. Patients will then undergo a 120-minute Digital Sedation™ program (Aqua+© 120 Version 1.1 or subsequent version, Oncomfort SA, Waver, Belgium). They will experience an underwater experience while listening to hypnotic script designed to induce a change in state of consciousness, increasing parasympathetic system tone and relaxation response, and reducing the perception of painful stimuli. While the session is running, HCPs can see what is projected into the VRH headset on their Sedakit's X2 controller (i.e. the tablet connected to the glasses).
Study NCT05707234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam sedation
Description: During the procedure, the patient in the control group receives pharmacological sedation, which is the standard of care currently practiced. Such sedation allows intraoperative anxiolysis, which is constantly required by patients in order to dissociate from their surroundings. Recall that total knee replacement surgery is extremely noisy, and the surrounding environment is itself an anxiety-provoking factor for the patient. Light to moderate, intraoperative sedation is carried out by intermittent boluses of midazolam 1 mg IV. Boluses are given every 5 minutes until a sedation level of -2 or -3 on the RASS (Richmond Agitation-Sedation Scale) scale is reached.